Answers are grounded in this paper and cite their sources.
Background Most sepsis subtyping strategies have been developed using unsupervised methods and were not specifically designed to quantify immune activation. Moreover, they often rely on categorical classifications, while a continuous representation may better capture sepsis immunobiology. Methods By integrating plasma cytokine response data with monocyte RNA sequencing profiles of 110 healthy volunteers who were intravenously challenged with 1 ng/kg lipopolysaccharide, we derived a continuous Innate Immunity Score (IIS), which we applied to five independent clinical cohorts of patients with sepsis ( n = 1267). We intersected the IIS with unsupervised established subtyping strategies (Mars, SRS, CTS, ARDS hyper/hypoinflammatory) and continuous sepsis scores (SRSq, lymphoid, and myeloid dysregulation scores). Furthermore, we performed an in-silico drug prediction analysis to explore potential therapeutics that reverse the transcriptomic signature associated with a high IIS, and explored heterogeneity of treatment effect (HTE) in sepsis for hydrocortisone using the IIS. A parsimonious classifier model was developed to support potential clinical applicability. Results The IIS was calculated based on the weighted expression of 46 genes that discriminated best between a high versus low plasma cytokine response to LPS administration in healthy volunteers. The IIS was associated with markers of immune activation, disease severity, organ dysfunction, and mortality in patients with sepsis. Several molecular pathways were uniquely upregulated (e.g. innate immune system) or downregulated (e.g. downstream Tcr signaling, generation of second messenger molecules, regulation of T-cell activation by CD28 family) in patients with a high IIS compared with established hyperinflammatory subtypes. A range of candidate drugs were predicted to reverse the transcriptional state associated with a high IIS, including corticosteroids, methotrexate, tyrosine kinase and mTOR inhibitors, and simvastatin. HTE was observed for hydrocortisone, suggesting harm for patients with a low IIS (≤ 0.66, 69% of patients) and benefit for those with a high IIS (> 0.66, 31%, p = 0.039). HTE could not be established using the SRSq ( p = 0.660), myeloid ( p = 0.648), or lymphoid ( p = 0.385) dysregulation scores. Finally, the three-gene ratio log 2 [( GPR84 , PIM1) : SLC27A1 ] accurately determined the IIS ( r = 0.91, p < 2.2 × 10 − 16 ; RMSE = 0.07). Conclusions A supervised, biologically informed continuous stratification approach reflecting immune activation in sepsis shows prognostic value and potential for treatment stratification. Therefore, it may provide a framework for exploring targeted immunomodulatory strategies. Trial registration CMO Arnhem-Nijmegen; reference no. NL68166.091.18 (registration date: 04-02-2019). Registered at Overview of Medical Research in the Netherlands (OMON) reference no. NL-OMON48466. Registered at ClinicalTrials.gov; reference no. NCT06801873.
No takes yet. Share an insight, caveat, or question.
Snoek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: